Results 291 to 300 of about 828,815 (378)
Objective Plasma biomarkers of Alzheimer's disease (AD) pathology are frequently tested in specialized research settings, which limits the generalizability of findings. Using electronic health records and banked plasma, we evaluated plasma biomarkers—phosphorylated tau 217 (p‐tau217), β‐amyloid 1–42/1–40 (Aβ42/Aβ40) and p‐tau217/Aβ42—in a real‐world ...
Katheryn A.Q. Cousins +12 more
wiley +1 more source
The Phenotypic Spectrum of Sporadic Creutzfeldt‐Jakob Disease Cortical Subtype
Objective The objective of this study was to characterize the phenotypic spectrum of the rare sporadic Creutzfeldt‐Jakob disease cortical subtype (sCJDMM/MV2C) in a large multicentric autopsy cohort. Methods We evaluated clinical histories, biofluid markers, brain diffusion‐weighted (DW)‐magnetic resonance imaging (MRI), and electroencephalogram (EEG ...
Simone Baiardi +16 more
wiley +1 more source
Objective Traumatic brain injury (TBI) is an established risk factor for dementia, although the underlying mechanisms remain unclear. Our previous research demonstrated that a single severe TBI in wild‐type (WT) mice induces a prion‐like form of tau (tauTBI) that spreads throughout the brain, leading to memory deficits.
Gloria Vegliante +19 more
wiley +1 more source
Objective Whether cognitive decline in patients with Parkinson's disease (PD) carrying GBA1 variants is accelerated after subthalamic deep brain stimulation (STN‐DBS) remains controversial. Clarifying long‐term cognitive outcomes is essential for informed decision making.
Moritz A. Loeffler +8 more
wiley +1 more source
Objective This 24‐month longitudinal study involving isolated rapid eye movement sleep behavior disorder (iRBD), early‐stage Parkinson's disease (PD), and matched healthy control subjects aimed to assess whether acoustic speech features from real‐world smartphone calls provide passive progressive biomarkers in synucleinopathies.
Michal Šimek +11 more
wiley +1 more source

